Biologics
- tumor necrosis factor alpha (TNF-alpha), which is a protein that promotes inflammation in the body
- T cells, which are white blood cells
- interleukins, which are cytokines (small inflammatory proteins) involved in psoriasis
Risankizumab-rzaa (Skyrizi)
approvedphototherapy- upper respiratory infections
- reactions at the injection site
- headache
- tiredness
- fungal infections
Certolizumab pegol (Cimzia)
approvedCimzia- upper respiratory tract infections
- rash
- urinary tract infections (UTIs)
Tildrakizumab-asmn (Ilumya)
FDA-approvedside effects of Ilumya- reactions at the injection site
- upper respiratory infections
- diarrhea
Guselkumab (Tremfya)
FDA-approved- headache
- upper respiratory infections
- reactions at the injection site
- joint pain
- diarrhea
- stomach flu
Brodalumab (Siliq)
FDA-approved- have moderate to severe plaque psoriasis
- are candidates for phototherapy or systemic therapy
- their psoriasis doesn’t respond to other systemic therapies
Ixekizumab (Taltz)
FDA-approvedmultiple clinical studies- upper respiratory infections
- reactions at the injection site
- fungal infections
Biosimilars to adalimumab (Humira)
- adalimumab-adaz (Hyrimoz)
- adalimumab-adbm (Cyltezo)
- adalimumab-afzb (Abrilada)
- adalimumab-atto (Amjevita)
- adalimumab-bwwd (Hadlima)
Biosimilars to etanercept (Enbrel)
- etanercept-szzs (Erelzi)
- etanercept-ykro (Eticovo)
Biosimilars to infliximab (Remicade)
- infliximab-abda (Renflexis)
- infliximab-axxq (Avsola)
- infliximab-dyyb (Inflectra)
Halobetasol propionate-tazarotene lotion, 0.01%/0.045% (Duobrii)
approved- pain at the application site
- rash
- folliculitis, or inflamed hair follicles
- wearing away of the skin where the lotion is applied
- excoriation, or skin picking
Halobetasol propionate foam, 0.05% (Lexette)
approvedbecame availableHalobetasol propionate lotion, 0.01% (Bryhali)
approved- dryness
- flaking
- inflammation
- plaque buildup
- burning
- stinging
- itching
- dryness
- upper respiratory tract infections
- high blood sugar
Betamethasone dipropionate spray, 0.05% (Sernivo)
approvedbetamethasone- itching
- burning
- stinging
- pain at the application site
- skin atrophy
Calcipotriene foam, 0.005% (Sorilux)
approvalapprovedCalcipotriene-betamethasone dipropionate foam, 0.005%/0.064% (Enstilar)
approved- itching
- folliculitis
- rash with raised red bumps or hives
- worsening psoriasis
Calcipotriene-betamethasone dipropionate topical suspension, 0.005%/0.064% (Taclonex)
FDA-approvedFDA-approved- itching
- burning
- irritation
- redness
- folliculitis
Ustekinumab (Stelara)
approvedustekinumabStelara2015 study- Adolescents who weigh less than 60 kilograms (132 pounds) get 0.75 milligrams (mg) per kilogram of weight.
- Adolescents who weigh between 60 kg (132 lbs.) and 100 kg (220 lbs.) get a 45-mg dose.
- Adolescents who weigh more than 100 kg (220 lbs.) get 90 mg, which is the standard dose for adults of the same weight.
- colds and other upper respiratory tract infections
- headache
- tiredness
Etanercept (Enbrel)
approvedEnbrel2016 studyBimekizumab
90 percent disease severityCalcipotriene-betamethasone dipropionate cream, 0.005%/0.064% (Wynzora)
phase III studyJAK inhibitors
- psoriatic arthritis
- rheumatoid arthritis
- ulcerative colitis